USD 24.64 Billion
Multiple Sclerosis Drugs Market Size, Share, Growth Analysis, By Drug Class(Immunomodulators and Immunosuppressant), By Mode of Administration(Oral and Injection (Intramuscular, Subcutaneous, Intravenous)), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35I2199 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|Tables:
62
|Figures:
77
Multiple Sclerosis Drugs Market Insights
Global Multiple Sclerosis Drugs Market size was valued at USD 25.40 billion in 2022 and is poised to grow from USD 26.19 billion in 2023 to USD 32.42 billion by 2031, at a CAGR of 3.10% during the forecast period (2024-2031).
Multiple sclerosis (MS) affects mental, emotional, physical, emotional, visual function and spinal cord. In recent years, the burden of multiple sclerosis seems to be increasing, increasing the demand for chemotherapeutics to adequately address multiple sclerosis. Thus, this increasing burden of multiple sclerosis will provide lucrative growth opportunities for the market during the forecast period.
The growth is attributed to the increasing focus on R&D to develop innovative drugs by major market players. For instance, in December 2020, Adamas Pharmaceuticals Inc. announced results from the phase 3 clinical study on ADS-5102, an investigational amantadine agent for treating MS patients. Product launches, increasing government initiatives to improve the accessibility of treatment & care, and the rising prevalence of multiple sclerosis are expected to result in the global market expansion.
Additionally, important pharmaceutical companies invest in drug development, such as MS treatments. This intranasal anti-CD3 monoclonal antibody, a fully human formulation, is intended for at-home self-administration. It is designed for patients with multiple sclerosis (MS). Thus, recent drug approvals and increased efforts by pharmaceutical companies to develop new therapies are driving market expansion.
US Multiple Sclerosis Drugs Market is poised to grow at sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Oral Route
Fastest Growth
Oral Route
Growth Rate
3.10% CAGR
Global Multiple Sclerosis Drugs Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Multiple Sclerosis Drugs Market Segmental Analysis
Global Multiple Sclerosis Drugs Market is segmented by drug class, mode of administration, distribution channel, and region. Based on drug class, the market can be segmented into Immunomodulators and Immunosuppressant. Based on mode of administration, the market is segmented into Oral and Injection (Intramuscular, Subcutaneous, Intravenous. Based on distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Analysis by Drug Class
The immunosuppressant segment currently dominates and is experiencing robust growth due to increasing autoimmune diseases, increasing worldwide organ transplantation rates and conditions such as rheumatoid arthritis, systemic lupus erythematosus and inflammatory. Success rates in postoperative and postoperative care have increased, leading to the demand for immunosuppressive drugs to prevent graft rejection. Drugs such as calcineurin inhibitors, antimetabolites and corticosteroids are widely used in this segment, with new biologic and monoclonal antibodies. Ongoing research also supports the development of drug-induced immune responses. The growth trajectory of immunosuppressants is also supported by ongoing research and development, which has led to the introduction of novel therapies targeting specific immune pathways.
Immunomodulators play an important role in the regulation of the immune response, which is exerted from the immune response against infections to organ transplants. Antibodies, which stimulate or suppress the immune system, are particularly valuable in conditions such as arthritis in infectious diseases. They help to maintain immune activity against pathogens or dampening it to prevent self-damage. The immunomodulator segment is on the rise due to its use in chronic diseases and the increasing demand for precision medicine. Therapies such as cytokine inhibitors and immunostimulants are central to personalized medicine strategies, as they offer customized ways to modulate the immune response based on patients’ individual cases.
Analysis by Distribution Channel
The hospital segment is dominated and has the highest growth driven by the increasing prevalence of acute and chronic diseases requiring specialized care. The use of advanced therapies such as biologics, monoclonal antibodies and gene therapy the larger requires professional care and infrastructure. Growth is considerable, including government and private players to invest more in hospitals to meet healthcare demand. The hospital phase is an important part of acute care and primary care. Hospitals are responsible for the delivery of complex treatments, such as intravenous drugs, chemotherapy and immunotherapy, which often require staff supervision and medical management. This category is essential for critical care, surgery, cancer, organ failure and infectious diseases that require immediate management. The trend towards centralized healthcare systems in many countries also supports hospitals following their dominance in delivering high-value care.
As per multiple sclerosis drugs market analysis, the pharmacy segment ensures access to continuity of care for outpatient needs. Pharmacies play an important role in the dispensing of medicines prescribed by health care providers and supply over-the-counter medicines, supplements and health care products. They are an important destination for patients suffering from chronic conditions such as diabetes, hypertension and asthma are addressed. They ensure availability in many areas, especially important in rural and underserved regions. But the pharmacy segment is also growing steadily, mainly due to increasing demand in outpatient settings, increased focus on convenience and accessibility and the proliferation of e-pharmacy.
Global Multiple Sclerosis Drugs Market By Route of Administration
To get detailed analysis on other segments, Request For Free Sample Report
Multiple Sclerosis Drugs Market Regional Insights
As per multiple sclerosis drugs market outlook, North America dominated the market in 2023. In addition, governments in the region are actively taking steps to raise awareness about MS treatment and diagnosis. The multiple sclerosis drugs market in the U.S. dominated the North America region with a share of 80.8% in 2023 due to the increased awareness leading to early detection of disease. According to the National Multiple Sclerosis Society, almost one million people in the U.S. were diagnosed with this condition in 2019. This underscores the rising prevalence of the disorder in the U.S.
The Asia Pacific region in the market is expected to register the highest CAGR during the forecast period. The region is witnessing a boost due to increased government initiatives, an increase in available treatment options, and lower treatment costs in the region. This tremendous growth is attributed to improved distribution systems of pharmaceutical companies in emerging markets. Additionally, in February 2018, Biogen and Eisai Co., Ltd. entered into a joint venture. signed an agreement to jointly promote Tecfidera, Tysabri, and Avonex in Japan. Moreover, increasing government initiatives in many countries to reduce MS treatment costs is another important factor driving the demand for MS drugs across the region.
Global Multiple Sclerosis Drugs Market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Multiple Sclerosis Drugs Market Dynamics
Multiple Sclerosis Drugs Market Drivers
Increasing Prevalence of Multiple Sclerosis
- The increasing prevalence of multiple sclerosis (MS) across the globe is a major driver of the multiple sclerosis drugs industry. According to the National Multiple Sclerosis Society, 2.8 million people worldwide have MS, and this number continues to rise, especially in the developed world. This growing number of patients requires new therapies to manage disease progression.
Advances in Drug Development
- Continuous advancements in the pharmaceutical industry, including the emergence of generics and oral formulations, propel the market forward. Traditional injectable DMTs are being administered or replaced by oral therapies such as fingolimod and siponimod, which improve patient compliance due to ease of administration. Furthermore, screening for monoclonal antibodies and the development of next-generation biotherapeutic-targeted-effective treatments. The approval of drugs with alternative mechanisms of action, such as B-cell depletion therapy, highlights the innovations driving the market.
Multiple Sclerosis Drugs Market Restraints
Increased Medical Costs
- High cost of MS treatment is a major barrier to market growth. Disease-modifying therapies, especially chemotherapy and other oral therapies, are often priced at premium levels, making them unaffordable for patients without robust insurance coverage. The financial burden is particularly pronounced in countries without access high-income and low-income countries, where Health systems do not have the resources to support such treatments.
Side Effects and Treatment-Associated Risks
- Side effects and risks associated with MS treatment are another important strategic aspect. While new therapies aim to reduce side effects, many currently used drugs are associated with significant complications including infection, liver damage, and cardiovascular events. These risks may deter patients from consumption prescriptions, affecting treatment efficacy and market growth.
Request Free Customization of this report to help us to meet your business objectives.
Multiple Sclerosis Drugs Market Competitive Landscape
The multiple sclerosis drugs industry is highly competitive, characterized by leading pharmaceutical companies that are constantly innovating and expanding their businesses. These companies are developing advanced disease modifying therapies (DMTs), generations of their vaccines, neuroprotective drugs to strengthen their market position. Competitive advantage focuses on pharmaceutical manufacturing as well. It is being shaped to gain market share in this growing segment through R&D efforts, strategic collaboration and marketing.
Multiple Sclerosis Drugs Market Top Player’s Company Profiles
- Biogen Inc. (United States)
- Roche Holdings AG (Switzerland)
- Novartis AG (Switzerland)
- Sanofi S.A. (France)
- Merck & Co., Inc. (United States)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bayer AG (Germany)
- Pfizer Inc. (United States)
- GlaxoSmithKline plc (United Kingdom)
- AbbVie Inc. (United States)
- Johnson & Johnson Services, Inc. (United States)
- Celgene Corporation (United States)
- Bristol-Myers Squibb Company (United States)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Biogen Idec International GmbH (Switzerland)
- Genzyme Corporation (United States)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Merck KGaA (Germany)
- Mylan N.V. (United States)
- Eisai Co., Ltd. (Japan)
- Takeda Pharmaceutical Company Limited (Japan)
- Ipsen (France)
Multiple Sclerosis Drugs Market Recent Developments
- March 2024: French pharmaceutical company Juvise Pharmaceuticals acquired worldwide marketing rights (except the United States and Canada) for Ponvori (ponesimod) indicated for the treatment of active adult relapsing multiple sclerosis.
- February 2024: Roche Pharma India by India launched the monoclonal antibody drug Ocrevus (ocrelizumab) as a disease-modifying therapy (DMT) for relapsing multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).
- In June 2022, Sandoz expanded its portfolio with Dimethyl fumararate HEXAL, a generic drug approved in Germany for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS).
Multiple Sclerosis Drugs Key Market Trends
- Rise in Personalized Medicine and Biomarker-based Therapy: One of the most important trends in the market is the shift towards personalized medicine. Advances in genetics and molecular biology allow the identification of biomarkers that can predict disease progression and treatment outcomes. This multiple sclerosis drugs market trend is driving the development of treatments tailored to meet the specific needs of individual patients.
- Increased Focus on Neuroprotection and Remyelination Therapies: Traditional treatments for MS focus on balancing the immune system to prevent disease recurrence, there is growing interest in developing neuroleptics protection and promoting remyelination. These treatments aim to repair damaged myelin sheaths and protect nerves. The success of such therapies could revolutionize MS treatment and expand the market.
Multiple Sclerosis Drugs Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to SkyQuest analysis, the multiple sclerosis drugs market is poised for growth, driven by rising prevalence of MS and continuous drug development. Key factors such as generic medicines and emergence of neuroprotective therapies set the market trend towards treatment delivery highly effective targeted. They also impede acceptance and access to treatment options. Despite these challenges, the market will continue to expand as pharmaceutical companies continue to invest in innovative solutions and precision therapies. By addressing the unmet needs of people with MS, including affordability and safety, the project has the potential to transform MS care, giving millions of people around the world hope that improved outcomes and quality of life.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 25.40 billion |
| Market size value in 2031 | USD 32.42 billion |
| Growth Rate | 3.10% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Multiple Sclerosis Drugs Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Multiple Sclerosis Drugs Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Multiple Sclerosis Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Multiple Sclerosis Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Multiple Sclerosis Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Multiple Sclerosis Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
